New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular disease

The journal Circulation published novel results based on data from the landmark EMPA-REG OUTCOME® trial, which suggest that treatment with empagliflozin positively impacts life expectancy in adults with type 2 diabetes and established cardiovascular dise https://www.newswire.ca/news-releases/new-analysis-estimates-the-positive-impact-of-empagliflozin-on-prolonging-life-expectancy-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease-699788791.html